Save the Baltic Sea – return unused medicines to your pharmacy

Drug residues that end up in water systems can damage the delicate ecosystem of seas and lakes. We can all help to improve the state of the Baltic Sea by taking old and unused medicines to the medicine collection points at pharmacies.

Read more

Drug development goes remote

Orion R&D’s own strengths build the foundation for success

Unprecedented spring challenged Orion

Adverse drug reactions are monitored to continuously improve patient safety

During the pandemic, desire to help and flexibility are also needed at a pharmaceutical company

We’ll get through this together

There is good availability of the medicines needed by Finns. Orion has increased production of several products during the spring.

Read more

Orion’s Sustainability Report 2019: Good progress was made towards the targets - but more work is needed

Towards a clean sea – The Baltic Sea region is our home

Pharmaceutical industry building emergency readiness

For years, the pharmaceutical industry has carried out proactive risk assessment and management on their global supply chains to ensure that medicines remain available at competitive prices.

Read more

Does coronavirus affect the availability of Orion’s pharmaceutical products?

We answer the most common questions related to the availability of Orion’s pharmaceutical products.

Read more

Medicine availability remains normal

The coronavirus pandemic has not compromised the supply of medicines in Finland or the rest of the EU. However, should the pandemic continue for a prolonged period, the availability of medicines may be affected.

Read more

From a medicine bottle to a flowerpot – fact and fiction about recycling medicine packages

Pharmaceutical packaging guarantees product integrity and much more

Without contract manufacturing, new drugs would enter the market at a much slower pace

Drug development from molecular level innovation to marketable product is rarely possible without collaboration and partnerships. Contract manufacturing allows pharmaceutical companies to outsource specific stages of development work to providers with the best available niche expertise.

Read more

Arrival of digital therapies to support patients and doctors

New digital tools benefit both patients and health care professionals, helping improve the treatment of Parkinson's disease, for example. They may also help ease the challenges of rising health care costs for public spending.

Read more

“It’s time to give back to the Baltic” – Orion provides funding of EUR 48,000 to the John Nurminen Foundation and #OURSEA campaign

This is Orion’s third year as a main sponsor of the John Nurminen Foundation. The Foundation’s new Baltic Sea campaigns will help minimise fertiliser emissions at ports and collect our fondest memories of the Baltic Sea.

Read more

#OURSEA kicks off at Helsinki International Boat Show: “This is the start of a super year for the Baltic Sea”

Read more

In the Yrityskylä learning environment, young people learn how the wheels of society turn

New pharmaceutical research utilising nanobiotechnology in Finland

A new research ecosystem has been set up in Finland in which the country’s leading research organisations, together with the Finnish Red Cross Blood Service, Orion Pharma and nanotechnology SMEs, are joining forces to develop new types of nanobiotechnological solutions for the treatment and early diagnostics of severe progressive diseases.

Read more

Orion continues to work for Baltic Sea protection by supporting the #OURSEA campaign

Read more

To ensure patients get their medicines

Orion implements responsible medication and states in its value proposition that it wants to be a medicine cabinet for Finns. Based on this, Orion is the sole manufacturer or distributor of many pharmaceuticals in Finland.

Read more

Artificial intelligence offers new possibilities for Orion's drug development

Investing benefits both investors and society

Orion aims to grow faster than the pharmaceutical market

Research and development are Orion's strengths, and the company will continue to invest in them. The target is to increase net sales 1.5-fold by 2025.

Read more

Energy Genius of the Year symbol for Fermion's plant in Oulu

Outi Vaarala leads innovative work to save cancer patients

The goal of research into rare diseases is to find new and effective treatments

Gypsum on fields protects the Baltic Sea from eutrophication

Artificial intelligence provides inspiration in drug development

New perspectives into children’s mental health issues

Going abroad was an important career move for Sara Sammallahti. A grant of EUR 50,000 from the Orion Research Foundation made it possible for her to join a group of Dutch and American researchers. Sammallahti is studying the effects of the mother’s well-being during pregnancy on the brain of the foetus.

Read more

A major grant took Suvi Kuosmanen abroad: Fascinated by cardiovascular genomics

Orion Corporation and The Solubility Company enter into collaboration to determine solubility of drug candidates using the innovative SPA method

A novel screening method enables faster and more accurate measurement.

Read more

Orion systematically promotes sustainability in its supply chain

LEVALS study results assessing the effects of oral levosimendan in patients with ALS published

The Phase 2 clinical trial (LEVALS) show encouraging results: in 66 patients supine SVC was significantly higher after 14 days treatment on oral levosimendan compared to placebo.

Read more

Biosimilars are a cost-effective option among biological medicines

Thanks to biosimilars, an increasing number of patients can receive effective care at a lower pharmaceutical cost.

Read more

A drug’s life cycle must not end in the Baltic Sea

Orion is one of the most popular employers in Finland

In Universum’s student survey on ideal workplaces Orion was ranked fourth by natural science students.

Read more

Mari Björkman: Cancer research – from idea to product

Serialisation improves patient safety